SCHEMBL2294348

SCHEMBL2294348

N#Cc1cccc(C(ON2C(=O)c3ccccc3C2=O)C(=O)N2CCOCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.47
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 4/20 0.44
PDCD1 Q15116 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
APLNR P35414 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MGLL Q99685 4/20 0.39
PIK3CD O00329 1/20 0.39
PIK3R2 O00459 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
PIK3R5 Q8WYR1 1/20 0.39
PIK3R3 Q92569 1/20 0.39
CASR P41180 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2290416 0.82 ALDH1A1 (0.42) TNFKMT2AALDH1A1MGLLCASR
SCHEMBL2294069 0.81 TNF (0.56) TNFKMT2APDCD1CD274MGLL
SCHEMBL2292893 0.76 TNF (0.50) TNFKMT2APDCD1CD274MGLL
SCHEMBL6689096 0.68 TNF (0.80) TNFGAAALDH1A1KDM4ETP53
SCHEMBL12420246 0.68 ALB (0.42) GAAALDH1A1SMN1; SMN2
SCHEMBL29482202 0.66 L3MBTL1 (0.62) KMT2AALDH1A1KDM4ESMN1; SMN2TP53
SCHEMBL4381752 0.66 KDM4E (0.52) GAAKMT2AALDH1A1KDM4ECASR
SCHEMBL13479739 0.66 TP53 (0.55) GAAKMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL6690089 0.65 TNF (1.00) TNFALDH1A1
SCHEMBL12282147 0.65 KMT2A (0.62) GAAKMT2AALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
EP-2164326-A1 AMIDE COMPOUNDS AND THE USE THEREOF Euro-Celtique, S.A. (LU) 2010-03-24 EP disclosed
WO-2008150447-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF CACNA1E, CACNA1B, CACNA1S TNF 3052/4885GAA 3413/4885KMT2A 2564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.